Eastern Ejiao's first quarter net revenue declined

April 29 evening, East E’Jiao released its quarterly report of 2019. According to the report, the total business income of E’Jiao in the first quarter was about 1.292 billion yuan, a decrease of about 23.83% compared with the same period last year, and its net profit was about 393 million yuan, a decrease of about 35.48% compared with the same period last year. In view of the double decline in net revenue in the first quarter, Donga-Ajiao said that it was mainly due to the reduction of inventory by downstream customers; the company integrated channels, pulled pure sales, controlled delivery, and consolidated terminal quality and foundation. It is worth noting that by the end of March 2019, the share-holding ratio of China Resources Pharmaceutical Investment had increased by 0.33% compared with the end of 2018. China Resources Pharmaceutical Investment and its co-actors, China Resources Donga Jiao, currently hold a total of 207 million shares, accounting for 31.59% of the total share capital of East Asia Asia Jiao.
Looking for chemical products? Let suppliers reach out to you!
2026-07-03
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Moderna to Cut 10 Percent of Staff as COVID Vaccine Sales Plunge Stock Drops 4 Percent
-
Sun Pharma Halts US Expansion Amid 25 Percent Tariff Threat Net Profit Drops 20 Percent
-
JB Pharma Q1 Net Profit Surges 14 Percent to ₹202 Crore Revenue Hits ₹1094 Crore with 30 Percent EBITDA Margin
-
Mounjaro Reduces Heart Events by 8 Percent More Than Trulicity in 13,000-Patient Diabetes Trial
-
Bayer Sets Aside $1.37 Billion for Roundup Lawsuits Raises 2025 Sales Forecast to €48 Billion
-
Trump Pressures 17 Pharma CEOs to Match US Drug Prices with Global Lows September 29 Deadline Set
-
Parliamentary Panel Urges Expanded Price Controls as Dozens of Cancer Drugs Remain Unregulated
-
Glenmark Recalls Over 110000 Bottles of BP and COPD Drugs in US Due to Safety Concerns
-
Novo Nordisk Reports Theft of Six Drug Batches in India Authorities Warn of Severe Patient Safety Risks
-
Platinum Chemotherapy Shortages Expose the Fragility of Essential API Supply
Recommend Reading
-
Glenmark Targets 10–15 Percent CAGR in India by Shifting to High-Margin Drugs AbbVie Deal and New Launches Boost Outlook
-
Wall Street Predicts New Obesity Pills Will Be Priced Near $1000 Like Wegovy and Zepbound Supply and Competition Pressures Mount
-
Haryana’s Drug Crackdown Gets Massive Public Support State Launches Podcast to Boost Community Involvement
-
Novo Nordisk Launches Wegovy in South Africa One in Two Adults Faces Obesity as GLP-1 Drug Competition Heats Up
-
Syndax Q2 Net Loss Widens to $71.8 Million Despite 43 Percent Revenue Surge and New Drug Momentum
-
China Fuel Oil 180CST Market Trends Show Slight Decline in Mid-August
-
Cost Support: Shandong Asphalt Market Rises in July
-
From Ancient Volcanoes to Modern Feed Mills: EFSA Validates Volcanic Zeolite as Safe and Effective Feed Additive
-
Chemours Partners with SRF Limited to Enhance Fluoropolymer and Intermediates Portfolio
-
Vietnam’s Seafood Exports Surge 20 Percent to $6.2 Billion China Hong Kong Overtakes US as Top Market Amid Trade Headwinds